静脈注射用鉄剤の世界市場2017-2021

【英語タイトル】Global Intravenous Iron Drugs Market 2017-2021

Technavioが出版した調査資料(IRTNTR12441)・商品コード:IRTNTR12441
・発行会社(調査会社):Technavio
・発行日:2017年4月12日
・ページ数:70
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥402,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥517,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥575,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、静脈注射用鉄剤の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、静脈注射用鉄剤の世界市場規模及び予測、製品別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About IV Iron Drugs
Iron is one of the most important minerals in the human body. One of the major components of hemoglobin, iron helps the blood carry oxygen. Iron deficiency can affect the production of hemoglobin and cause anemia. This condition is known as iron deficiency anemia.

Technavio’s analysts forecast the global IV iron drugs market to grow at a CAGR of 10.46% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global IV iron drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of IV iron drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global IV Iron Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos

[Other prominent vendors]
• Nippon Shinyaku
• NOXXON Pharma
• Rockwell Medical
• Sanofi
• Wanbang Biopharmaceutical

[Market driver]
• Growing demand for non-dextran intravenous iron drugs
• For a full, detailed list, view our report

[Market challenge]
• Presence of substitutes coupled with growing research activities for new alternatives
• For a full, detailed list, view our report

[Market trend]
• Increase in favorable guidelines from healthcare organizations
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Find more reports on related topics – https://www.spendedge.com/

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of iron deficiency

PART 06: Pipeline landscape

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by product type
• Ferric carboxymaltose
• Sucrose
• Dextran
• Others

PART 09: Geographical segmentation
• Intravenous iron drugs market in Americas
• Intravenous iron drugs market in EMEA
• Intravenous iron drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Increase in favorable guidelines from healthcare organizations
• Increasing strategies of vendors to expand reach of intravenous iron drugs
• Growing focus on emerging economies

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos
• Other prominent vendors

PART 15: Appendix
• List of abbreviation

[List of Exhibits]

Exhibit 01: Pipeline landscape
Exhibit 02: Global intravenous iron drugs market
Exhibit 03: Annual shipment sales growth of Ferinject/Injectafer in key countries in 2015
Exhibit 04: Global intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 05: Global intravenous iron drugs market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Ferric carboxymaltose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 09: Global sucrose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 10: Global dextran-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 11: Global other intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 12: Global intravenous iron drugs market by geography 2016 and 2021
Exhibit 13: Global intravenous iron drugs market by geography: Revenue 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Intravenous iron drugs market in the Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Intravenous iron drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Intravenous iron drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Impact of drivers
Exhibit 21: Cost comparison of key drugs per week 2015 ($)
Exhibit 22: Cost comparison of key drugs per treatment 2015 ($)
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global intravenous iron drugs market 2016
Exhibit 25: Market share analysis 2016
Exhibit 26: Competitive analysis of global intravenous iron drugs market
Exhibit 27: Strategic success factors of companies in global intravenous iron drugs market
Exhibit 28: Allergan: Strength assessment
Exhibit 29: Allergan: Strategy assessment
Exhibit 30: Allergan: Opportunity assessment
Exhibit 31: AMAG Pharmaceuticals: Key highlights
Exhibit 32: AMAG Pharmaceuticals: Strength assessment
Exhibit 33: AMAG Pharmaceuticals: Strategy assessment
Exhibit 34: AMAG Pharmaceuticals: Opportunity assessment
Exhibit 35: AMAG Pharmaceuticals: YoY revenue and growth rate of Feraheme ($ millions)
Exhibit 36: Daiichi Sankyo: Key highlights
Exhibit 37: Daiichi Sankyo: Strength assessment
Exhibit 38: Daiichi Sankyo: Strategy assessment
Exhibit 39: Daiichi Sankyo: Opportunity assessment
Exhibit 40: Daiichi Sankyo: YoY revenue and growth rate of Injectafer 2013-2015 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 42: Galenica: Key highlights
Exhibit 43: Galenica: Strength assessment
Exhibit 44: Galenica: Strategy assessment
Exhibit 45: Galenica: Opportunity assessment
Exhibit 46: Galenica: YoY revenue and growth rate of Ferinject 2013-2015 ($ millions)
Exhibit 47: Galenica: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 48: Pharmacosmos: Key highlights
Exhibit 49: Pharmacosmos: Strength assessment
Exhibit 50: Pharmacosmos: Strategy assessment
Exhibit 51: Pharmacosmos: Opportunity assessment



【掲載企業】

Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, Pharmacosmos, Nippon Shinyaku, NOXXON Pharma, Rockwell Medical, Sanofi, and Wanbang Biopharmaceutical

【レポートのキーワード】

静脈注射用鉄剤、鉄欠乏性貧血、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[静脈注射用鉄剤の世界市場2017-2021] (コード:IRTNTR12441)販売に関する免責事項を必ずご確認ください。
★調査レポート[静脈注射用鉄剤の世界市場2017-2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆